In Vivo |
Fargesone A (3 and 30 mg/kg; i.p.; daily for 7 days) 可显著改善胆管结扎 (BDL) 诱导的慢性肝纤维化小鼠模型[1]。 Pharmacokinetics parameters of Fargesone A in mice t1/2 (h) Tmax (h) Cmax (ng/mL) AUC0-t (ng/mL*h) AUC0-inf (ng/mL*h) MRT0-inf (h) F (%) i.v. (5 mpk) 0.68±0.1 - 941±57 469±13 471±14 0.43±0.13 - p.o. (10 mpk) 0.33±0.04 0.25±0.00 104±16 101±32 102±32 0.58±0.07 10.8±3.2 Animal Model: C57BL/6 mice, bile duct ligation (BDL)-induced chronic liver fibrosis mouse model[1] Dosage: 3 and 30 mg/kg Administration: IP, once daily for 7 days Result: Resulted in a lower level of inflammatory infiltrates and a smaller amount of collagen deposition compared to the vehicle group. Reversed BDL-induced sharp increase in total bilirubin level in the serum. Significantly decreased liver mRNA expression of the inflammatory biomarkers interleukin (IL)-6, IL-1β, inducible nitric oxide synthase (iNOS), and prostaglandin-endoperoxide synthase 2 (COX2). Animal Model: C57BL6/J mice[1] Dosage: 5 or 10 mg/kg Administration: IV or PO (Pharmacokinetics Analysis) Result: Showed acceptable PK profiles in general.
|